About ProQR Therapeutics N.V.
https://www.proqr.comProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders.
CEO
Daniel Anton de Boer
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Chardan Capital
Buy
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Oppenheimer
Outperform
Cantor Fitzgerald
Overweight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:6.25M
Value:$10.26M
PRIVIUM FUND MANAGEMENT B.V.
Shares:5M
Value:$8.2M
AFFINITY ASSET ADVISORS, LLC
Shares:3.6M
Value:$5.9M
Summary
Showing Top 3 of 72
About ProQR Therapeutics N.V.
https://www.proqr.comProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.92M ▼ | $14.2M ▼ | $-11.01M ▲ | -377.56% ▼ | $-0.1 ▲ | $-10.34M ▲ |
| Q2-2025 | $3.82M ▼ | $16.07M ▲ | $-12.18M ▼ | -319.07% ▼ | $-0.12 ▼ | $-11.57M ▼ |
| Q1-2025 | $4.52M ▲ | $15.34M ▲ | $-10.08M ▼ | -223.04% ▼ | $-0.1 ▲ | $-10.14M ▼ |
| Q4-2024 | $4.31M ▲ | $14.39M ▲ | $-9.3M ▼ | -216.04% ▼ | $-0.11 ▼ | $-5.82M ▲ |
| Q3-2024 | $3.84M | $12.56M | $-8.11M | -210.98% | $-0.1 | $-8.17M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $106.88M ▼ | $124.35M ▼ | $67.28M ▼ | $57.07M ▼ |
| Q2-2025 | $119.77M ▼ | $137.54M ▼ | $70.55M ▼ | $66.98M ▼ |
| Q1-2025 | $143.03M ▼ | $163.85M ▼ | $78.59M ▼ | $85.27M ▼ |
| Q4-2024 | $149.41M ▲ | $167.96M ▲ | $79.4M ▼ | $88.56M ▲ |
| Q3-2024 | $89.4M | $106.85M | $81.87M | $24.98M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-11.01M ▲ | $-12.23M ▼ | $-169K ▼ | $-444K ▼ | $-12.88M ▼ | $-12.4M ▼ |
| Q2-2025 | $-12.18M ▼ | $-11.4M ▲ | $-101K ▲ | $-293K ▲ | $-12.65M ▲ | $-11.5M ▲ |
| Q1-2025 | $-10.08M ▼ | $-15.8M ▼ | $-224K ▲ | $-500K ▼ | $-16.99M ▼ | $-16.02M ▼ |
| Q4-2024 | $-9.3M ▼ | $-9.35M ▼ | $-2.79M ▼ | $71.43M ▲ | $60.01M ▲ | $-9.48M ▼ |
| Q3-2024 | $-8.11M | $-5.66M | $16.71M | $-453K | $10.43M | $-5.94M |
CEO
Daniel Anton de Boer
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Chardan Capital
Buy
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Oppenheimer
Outperform
Cantor Fitzgerald
Overweight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:6.25M
Value:$10.26M
PRIVIUM FUND MANAGEMENT B.V.
Shares:5M
Value:$8.2M
AFFINITY ASSET ADVISORS, LLC
Shares:3.6M
Value:$5.9M
Summary
Showing Top 3 of 72